Rezolute (RZLT) insider purchase: 1.23 M shares acquired at $3.25

Rhea-AI Filing Summary

Form 4 overview: Rezolute, Inc. (RZLT) disclosed that director Young-Jin Kim executed a substantial open-market purchase of the company’s common stock on 13 June 2025.

• Transaction code P (Purchase): 1,230,769 common shares acquired indirectly through Handok, Inc. at $3.25 per share, implying a cash outlay of roughly $4.0 million.
• Post-transaction holdings: Handok, Inc. now holds 8,423,386 shares (indirect ownership attributed to Kim). Kim also continues to hold 149,950 shares directly; no change was reported for the direct position.
• The filing states that Kim “disclaims beneficial ownership” of Handok’s holdings except to the extent of any pecuniary interest, but SEC rules still require attribution because he is a director of Rezolute and a control person at Handok.

Investment take-aways:

• A multi-million-dollar insider purchase often signals personal or strategic confidence in Rezolute’s pipeline and valuation.
• The purchase increases Handok’s stake and may strengthen the strategic relationship between the two companies, as Handok has historically been a significant investor and commercial partner.
• No derivative transactions, sales, or option exercises were reported, underscoring a purely additive position.

The Form 4 contains no earnings metrics, operational updates or forward-looking statements; the filing is limited to reporting the insider trade required under Section 16(a).

Positive

• Substantial insider purchase: 1,230,769 shares bought for ≈$4 million, indicating confidence from a board member.
• Stake increase: Handok, Inc. now controls 8,423,386 shares, potentially aligning strategic partner interests with common shareholders.
• No offsetting sales: Filing shows only acquisitions, reinforcing the additive nature of the trade.

Negative

• None.

Insights

Financial Analyst

TL;DR: Director bought 1.23 M shares for ≈$4 M, raising indirect stake to 8.4 M—signal skews positive.

The size of the purchase—about 1.2 million shares at $3.25—represents a material capital commitment that exceeds typical insider buying thresholds. Such accumulation by a board member, particularly via a long-standing strategic investor (Handok), is normally interpreted as confidence in Rezolute’s clinical catalysts and funding outlook. Because the purchase is open-market (not option-related) and no offsetting sales occurred, it improves alignment between management and shareholders. However, investors should note that the ownership is indirect and Kim disclaims full beneficial ownership; future dispositions by Handok could still occur. On balance, the transaction is a modestly positive, potentially impactful signal.

Portfolio Manager

TL;DR: Large insider buy adds to strategic holder’s stake—likely positive, limited immediate valuation effect.

From a portfolio-allocation lens, a $4 million insider buy in a micro/small-cap biotech increases conviction but does not alone alter risk-reward. The purchase lifts Handok’s stake above 8 million shares, possibly tightening the trading float and adding a friendly block holder. Liquidity impact is neutral because shares were acquired in the market at prevailing prices. While insider accumulation typically supports share price, the ultimate driver remains Rezolute’s late-stage clinical data and funding runway. I classify the news as positive but not transformative.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kim Young-Jin

(Last) (First) (Middle)

C/O REZOLUTE, INC.

275 SHORELINE DRIVE, SUITE 500

(Street)

REDWOOD CITY CA 94065

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Rezolute, Inc. [ RZLT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/13/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	06/13/2025		P		1,230,769	A	$3.25	8,423,386	I	Held by Handok, Inc.(1)
Common Shares								149,950	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reporting person disclaims beneficial ownership of the securities held by Handok, Inc. except to the extent of his pecuniary interest therein, if any.

	/s/ Young-Jin Kim	06/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Rezolute (RZLT) shares did Young-Jin Kim purchase?

The director indirectly purchased 1,230,769 common shares at $3.25 each.

What was the total cost of the insider purchase reported on the Form 4?

At $3.25 per share, the purchase equates to roughly $4.0 million.

What is Young-Jin Kim’s total holding after the transaction?

He beneficially owns 8,423,386 shares indirectly through Handok plus 149,950 shares directly.

Did the Form 4 disclose any stock sales or derivative exercises?

No. The filing reports only a purchase; no sales or derivative transactions were disclosed.

Why is the ownership marked as indirect on the Form 4?

The shares are held by Handok, Inc.; as a director and affiliate, Kim’s interest is attributed to him under SEC rules.